CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for IR Biosciences Holdings, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

IR Biosciences Holdings, Inc.
8777 E. Via De Ventura, Suite 280
Phone: (480) 922-3926p:480 922-3926 SCOTTSDALE, AZ  85258  United States Ticker: IRBSIRBS
Business Summary
IR BioSciences Holdings, Inc. is a development-stage biotechnology company. The Company, through its wholly owned subsidiary, ImmuneRegen BioSciences, Inc. (ImmuneRegen), is engaged in the research and development of the drug candidate Homspera for use in therapies in pulmonology, immunology and hematology. The Company focuses on the research and development of therapies in the areas of pulmonary fibrosis, influenza infection and radiation-induced Neutropenia. Other areas of research include vaccine adjuvant activity evinced against certain forms of cancer and applications for wound healing and for regenerating or strengthening the human immune system, in part, through stimulating human adult stem cells.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201012/31/2009YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
7375 Information retrieval services
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director Michael K.Wilhelm 45 7/1/2003 7/1/2003
Chief Financial Officer John N.Fermanis 58 12/22/2004 12/22/2004
Vice President, Chief Scientific Officer, Director Hal N.Siegel 57 1/1/2008 6/1/2006
4 additional Officers and Directors records available in full report.

Business Names
Business Name
GPN NETWORK INC
GPN Network, Inc.
IR BIOSCIENCES HOLDINGS INC
4 additional Business Names available in full report.

General Information
Number of Employees: 4 (As of 12/31/2010)
Outstanding Shares: 17,082,963 (As of 5/20/2011)
Shareholders: 517
Stock Exchange: OTC
Federal Tax Id: 133301899
Fax Number: (302) 636-5454


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 29, 2023